Galecto Inc. (GLTO)
3.41
-0.02 (-0.58%)
At close: Mar 28, 2025, 3:59 PM
3.44
0.99%
After-hours: Mar 28, 2025, 06:55 PM EDT
Company Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Galecto Inc.
| Country | United States |
| IPO Date | Oct 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Dr. Hans T. Schambye M.D., Ph.D. |
Contact Details
Address: 75 State Street Boston, Massachusetts United States | |
| Website | https://galecto.com |
Stock Details
| Ticker Symbol | GLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001800315 |
| CUSIP Number | 36322Q107 |
| ISIN Number | US36322Q1076 |
| Employer ID | 37-1957007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Director |
| Lori C. Firmani | Interim Chief Financial Officer |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Garrett Winslow Esq. | Senior Vice President, General Counsel & Corporate Secretary |
| Matthew Kronmiller | EVice President of Strategy & Chief Business Officer |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Ulf J. Nilsson Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | S-8 | Filing |
| Mar 19, 2025 | 10-K | Annual Report |
| Jan 16, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 01, 2024 | 10-Q | Quarterly Report |